Lipid Sciences, Inc. (NASDAQ: LIPD) announced today that the first patient procedure has been completed in the Company’s human clinical trial: “A Randomized Single-Blind, Placebo Controlled Study to Evaluate the Safety of the Lipid Sciences’ Plasma Delipidation System-2 (PDS-2) in Subjects with Prior Acute Coronary Syndrome.” The trial is being conducted at the Washington Hospital Center (WHC) in Washington, D.C. Dr. Ron Waksman, Associate Director, Division of Cardiology, at Washington Hospital Center, and an internationally recognized intravascular ultrasound (IVUS) specialist, is the principal investigator for the trial.
